About Us
Our Approach & Focus
About microRNAs
Pipeline
Patients
Publications
News & Events
Contact
Contact Us
News & Events
News
September 28, 2023
ARTHEx Biotech to Present at Chardan’s 7th Annual Genetic Medicines Conference
August 29, 2023
ARTHEx Biotech to Present Preclinical Data on ATX-01 for Myotonic Dystrophy Type 1 (DM1) at RNA Leaders USA Congress
May 9, 2023
ARTHEx Biotech to Present Preclinical Data on ATX-01 for Myotonic Dystrophy Type 1 (DM1) at TIDES USA 2023 Meeting
May 3, 2023
ARTHEx Biotech Announces Closing of €42 M Series B Financing to Advance ATX-01, its Novel Treatment for Myotonic Dystrophy Type 1 (DM1)
December 15, 2022
Arthex announces regulatory milestones met in its program to develop ATX-01 in Myotonic Dystrophy Type 1
November 28, 2022
Arthex Biotech appoints Frédéric Legros, Ph.D., as Executive Chairman of the Board
October 25, 2022
Arthex Biotech Selected for EIC Accelerator Award of up to 14 Million Euros
July 20, 2022
ARTHEx Biotech announces ATX-01 has been granted Orphan Drug Designation by the FDA
June 6, 2022
ARTHEx biotech drug delivery Platform: Enhancing antimiR delivery to treat unmet diseases
Next
Events
September 6–7, 2023
RNA Leaders USA Congress
May 7 – 10, 2023 | San Diego, CA USA
TIDES USA - Oligonucleotide & Peptide Therapeutics
Bassel. September 21-22, 2022
22ND ANNUAL BIOTECH IN EUROPE FORUM
November 16-18, 2022, Vienna
TIDES Europe
October 2-5,2022, Phoenix
18th Annual Meeting of the Oligonucleotide Therapeutics Society
September 9-10, 2022; San Diego
2022 MDF Annual Conference